Libtayo could capture up to $1 billion in sales from the NSCLC category, according to analysts, although additional upside is possible if an ongoing combination study yields positive results.
Zacks.com on MSN29d
Regeneron Gets Positive CHMP Opinion for Multiple Myeloma DrugThe positive CHMP opinion is supported by data ... which currently comprises Libtayo (cemiplimab-rwlc), indicated in certain ...
Along with first-line PDL1-positive NSCLC, Libtayo is also used to treat two forms of skin cancer – cutaneous squamous cell carcinoma and basal cell carcinoma. Merck claims adjuvant win in ...
Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that the completion ...
Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with ...
in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer (NSCLC). Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback